EEG-mapping differences between narcolepsy patients and controls and subsequent double-blind, placebo-controlled...

Area of Science:

• Neuroscience
• Sleep Medicine
• Psychopharmacology

Background:

• Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness and disrupted sleep-wake cycles.
• Objective and subjective measures are used to assess vigilance deficits in narcolepsy, but their comparative efficacy requires further investigation.
• Electroencephalography (EEG) mapping offers a quantitative approach to evaluating brain activity related to vigilance.

Purpose of the Study:

• To evaluate EEG mapping as an objective measure of vigilance in narcolepsy.
• To compare EEG mapping with the Multiple Sleep Latency Test (MSLT) and Epworth Sleepiness Scale (ESS).
• To assess the efficacy of modafinil in improving vigilance in narcolepsy using these measures.

Main Methods:

• 16 drug-free narcoleptic patients and 16 healthy controls underwent baseline EEG recordings (resting and vigilance-controlled).
• A double-blind, placebo-controlled crossover study assessed modafinil (200-400 mg/day) effects on EEG mapping, MSLT, and ESS.
• EEG spectral analysis identified vigilance decrements characterized by increased theta power and decreased alpha/beta power.

Main Results:

• Untreated narcoleptics showed significant EEG differences compared to controls, indicating vigilance deficits.
• Modafinil 400 mg/day significantly improved vigilance compared to placebo, with EEG changes opposing baseline deficits.
• EEG mapping demonstrated strong correlations with ESS and MSLT, suggesting its utility in assessing treatment response.

Conclusions:

• EEG mapping is a valuable tool for objectively quantifying vigilance impairments in narcolepsy.
• Modafinil effectively improves vigilance in narcolepsy, as evidenced by EEG mapping and other clinical measures.
• EEG mapping provides a reliable method for monitoring treatment efficacy of psychostimulants in narcolepsy.